TY  - JOUR
AU  - Leichsenring, Jonas
AU  - Vladimirova, Valentina
AU  - Solbach, Christine
AU  - Karn, Thomas
AU  - Ataseven, Beyhan
AU  - Sinn, Bruno Valentin
AU  - Barinoff, Jana
AU  - Müller, Volkmar
AU  - Blohmer, Jens-Uwe
AU  - Schem, Christian
AU  - Engels, Knut
AU  - Marmé, Frederik
AU  - Fisseler-Eckhoff, Annette
AU  - Fasching, Peter A
AU  - Stickeler, Elmar
AU  - van Mackelenbergh, Marion
AU  - Denkert, Carsten
AU  - Stenzinger, Albrecht
AU  - Loibl, Sibylle
AU  - Gröschel, Stefan
TI  - EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
JO  - BMC cancer
VL  - 22
IS  - 1
SN  - 1471-2407
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2022-02327
SP  - 1040
PY  - 2022
N1  - #LA:A380#
AB  - Overexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we aimed to investigate frequency and clinical relevance of EVI1 expression in newly diagnosed BC treated with neoadjuvant chemotherapy.EVI1 expression was determined by immunohistochemistry using H-score as a cumulative measurement of protein expression in pretherapeutic biopsies of BC patients treated with anthracycline/taxane based neoadjuvant chemotherapy within the GeparTrio trial. EVI1 was analyzed as a continuous variable and dichotomized into low or high based on median expression. Endpoints were pathological complete response (pCR), disease-free survival (DFS) and overall survival (OS).Of the 993 tumors analyzed, 882 had available subtype information: 50.8
KW  - Breast cancer (Other)
KW  - EVI1 (Other)
KW  - Neoadjuvant chemotherapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36195836
DO  - DOI:10.1186/s12885-022-10109-1
UR  - https://inrepo02.dkfz.de/record/181957
ER  -